Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSala Cunill, Anna
dc.contributor.authorAlmeida-Sánchez, Zulay M.
dc.contributor.authorGarcía-Núñez, Ignacio
dc.contributor.authorLaín, Sofia
dc.contributor.authorMartínez-Tadeo, Juan A.
dc.contributor.authorMartos, Maria D.
dc.date.accessioned2022-04-06T11:43:50Z
dc.date.available2022-04-06T11:43:50Z
dc.date.issued2021-07-01
dc.identifier.citationSala-Cunill A, Almeida-Sánchez ZM, García-Núñez I, Laín S, Martínez-Tadeo JA, Martos MD, et al. Real-World Safety and Effectiveness Evidence of a Microcrystalline Tyrosine-Associated Mite Allergoid in Children and Adolescents with Allergic Rhinitis. Allergol Immunopathol. 2021;49(4):98–108.
dc.identifier.issn1578-1267
dc.identifier.urihttp://hdl.handle.net/11351/7318
dc.descriptionAllerghic rhinitis; Children and adolescents; Microcrystalline tyrosine
dc.description.abstractEvidence regarding allergen immunotherapy (AIT) in pediatric population is scarce. We have assessed safety and effectiveness of subcutaneous AIT with a microcrystalline tyrosine (MCT)-associated mite allergoid, Acarovac Plus®, in children and adolescents with allergic rhinitis (AR), with and without asthma, in the real-world setting. This was a retrospective, multicenter study including children and adolescents aged 5 years to 17 years with AR, with and without asthma, and sensitized to mites, receiving AIT with Acarovac Plus® during ≥6 months. Primary and secondary objectives were safety and effectiveness, respectively. Effectiveness variables were assessed during 12 months before and after AIT and included unscheduled visits to the healthcare center and emergency room admissions, rhinitis and asthma symptoms according to ARIA and GEMA classifications, respectively, medication use, and patients’ and physicians’ disease perception graded on a visual analog scale (VAS). All 79 patients included had a mean (SD) age of 12.7 (3.3) years. Two patients experienced systemic adverse reactions (none severe). Unscheduled visits to the healthcare center and emergency room admissions decreased (mean (SD) 3.02 [2.48] and 0.63 [1.35] vs. 1.08 [1.38] and 0.09 [0.38], before and after treatment, p < 0.001 and p = 0.001, respectively). After AIT, rhinitis and asthma classification changed (p < 0.0001 for all classifications), showing improvements in symptoms and a significant decrease in rhinitis and use of medication for asthma and VAS scores grading patients’ and physicians’ disease perception (p < 0.001). In conclusion, these results show that AIT with an MCT-associated mite allergoid appears safe and effective in children and adolescents with AR treated in the real-world setting.
dc.language.isoeng
dc.publisherCODON Publications
dc.relation.ispartofseriesAllergologia et immunopathologia;49(4)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectÀcars
dc.subjectImmunosupressió
dc.subjectRinitis - Tractament
dc.subject.meshRhinitis, Allergic
dc.subject.mesh/therapy
dc.subject.meshDesensitization, Immunologic
dc.subject.meshMites
dc.titleReal-World Safety and Effectiveness Evidence of a Microcrystalline Tyrosine-Associated Mite Allergoid in Children and Adolescents with Allergic Rhinitis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.15586/aei.v49i4.195
dc.subject.decsrinitis alérgica
dc.subject.decs/terapia
dc.subject.decsdesensibilización inmunológica
dc.subject.decsácaros
dc.relation.publishversionhttps://doi.org/10.15586/aei.v49i4.195
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Sala-Cunill A] Secció d’Al·lèrgia, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Almeida-Sánchez ZM] Hospital General de la Palma, La Palma, Spain. [García-Núñez I] Pneumokal Research Institute, S.L. Estepona, Málaga, Spain. Allergology and Pneumology Department, Hospital Quirónsalud Campo de Gibraltar, Cádiz, Spain. [Laín S] Hospital General de Catalunya, Sant Cugat del Vallès, Spain. [Martínez-Tadeo JA] Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain. [Martos MD] Hospital de Torrevieja, Alicante, Spain
dc.identifier.pmid34224224
dc.identifier.wos000669521100013
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record